We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to ...

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment prolongs survival.

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

NDV-01 is protected by patents that extend to 2038.

Jethro C.C. Kwong, a urology resident from the University of Toronto, discusses a novel artificial intelligence (AI)-based ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for ...

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

LAS VEGAS, April 28, 2025 (GLOBE NEWSWIRE) -- Groundbreaking research presented at the American Urological Association (AUA) Annual Meeting in Las Vegas is shining a spotlight on the hidden ...

Shares of Protara Therapeutics, Inc. (NASDAQ: TARA) tumbled 19% after the company released interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with Non-Muscle Invasive ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.